NCT00337779View on ClinicalTrials.gov

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

PHASE3CompletedINTERVENTIONAL
Enrollment

1,155

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

Glatiramer Acetate (GA) 40 mg

Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months

DRUG

glatiramer acetate 20 mg

Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00337779 - Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). | Biotech Hunter | Biotech Hunter